Terms: = Bone cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Treatment
16 results:
1. PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.
Si Z; Shen Z; Luan F; Yan J
J Orthop Surg Res; 2023 Feb; 18(1):132. PubMed ID: 36823640
[TBL] [Abstract] [Full Text] [Related]
2. The COPS3-foxo3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma.
Niu J; Yan T; Guo W; Wang W; Ren T; Huang Y; Zhao Z; Yu Y; Chen C; Huang Q; Lou J; Guo L
Autophagy; 2023 Jun; 19(6):1693-1710. PubMed ID: 36451342
[TBL] [Abstract] [Full Text] [Related]
3. Acetylshikonin induces apoptosis of human osteosarcoma U2OS cells by triggering ROS-dependent multiple signal pathways.
Cha HS; Lee HK; Park SH; Nam MJ
Toxicol In Vitro; 2023 Feb; 86():105521. PubMed ID: 36410617
[TBL] [Abstract] [Full Text] [Related]
4. foxo3a-dependent up-regulation of HSP90 alleviates cisplatin-induced apoptosis by activating FUNDC1-mediated mitophagy in hypoxic osteosarcoma cells.
Lu D; Liu R; Zhou Y; Zhang Z; Jiang X; Xu J; Su A; Hu Z
Cell Signal; 2023 Jan; 101():110500. PubMed ID: 36270475
[TBL] [Abstract] [Full Text] [Related]
5. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
García-Valverde A; Rosell J; Sayols S; Gómez-Peregrina D; Pilco-Janeta DF; Olivares-Rivas I; de Álava E; Maurel J; Rubió-Casadevall J; Esteve A; Gut M; Valverde C; Barretina J; Carles J; Demetri GD; Fletcher JA; Arribas J; Serrano C
Oncogene; 2021 Dec; 40(48):6614-6626. PubMed ID: 34621020
[TBL] [Abstract] [Full Text] [Related]
6. Proteasome inhibitor MG132 induces apoptosis in human osteosarcoma U2OS cells.
Lee HK; Park SH; Nam MJ
Hum Exp Toxicol; 2021 Nov; 40(11):1985-1997. PubMed ID: 34002651
[TBL] [Abstract] [Full Text] [Related]
7. EGFR/foxo3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide.
Ciechomska IA; Gielniewski B; Wojtas B; Kaminska B; Mieczkowski J
Exp Mol Med; 2020 Aug; 52(8):1326-1340. PubMed ID: 32788653
[TBL] [Abstract] [Full Text] [Related]
8. A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells.
Vares G; Ahire V; Sunada S; Ho Kim E; Sai S; Chevalier F; Romeo PH; Yamamoto T; Nakajima T; Saintigny Y
Radiother Oncol; 2020 Sep; 150():253-261. PubMed ID: 32717360
[TBL] [Abstract] [Full Text] [Related]
9. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Stefka AT; Johnson D; Rosebeck S; Park JH; Nakamura Y; Jakubowiak AJ
Cancer Med; 2020 Jan; 9(1):324-334. PubMed ID: 31714026
[TBL] [Abstract] [Full Text] [Related]
10. Circulating IGF-1 promotes prostate adenocarcinoma via foxo3A/BIM signaling in a double-transgenic mouse model.
Wang S; Wang N; Yu B; Cao M; Wang Y; Guo Y; Zhang Y; Zhang P; Yu X; Wang S; Zeng L; Liang B; Li X; Wu Y
Oncogene; 2019 Sep; 38(36):6338-6353. PubMed ID: 31312023
[TBL] [Abstract] [Full Text] [Related]
11. Brazilin induces foxo3A-dependent autophagic cell death by disturbing calcium homeostasis in osteosarcoma cells.
Kang Y; He P; Wang H; Ye Y; Li X; Xie P; Wu B
Cancer Chemother Pharmacol; 2018 Sep; 82(3):479-491. PubMed ID: 29987368
[TBL] [Abstract] [Full Text] [Related]
12. Activation of autophagy by foxo3 regulates redox homeostasis during osteogenic differentiation.
Gómez-Puerto MC; Verhagen LP; Braat AK; Lam EW; Coffer PJ; Lorenowicz MJ
Autophagy; 2016 Oct; 12(10):1804-1816. PubMed ID: 27532863
[TBL] [Abstract] [Full Text] [Related]
13. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.
Murray ME; Gavile CM; Nair JR; Koorella C; Carlson LM; Buac D; Utley A; Chesi M; Bergsagel PL; Boise LH; Lee KP
Blood; 2014 Jun; 123(24):3770-9. PubMed ID: 24782505
[TBL] [Abstract] [Full Text] [Related]
14. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract] [Full Text] [Related]
15. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract] [Full Text] [Related]
16. Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Dewar R; Chen ST; Yeckes-Rodin H; Miller K; Khosravi-Far R
Cancer Biol Ther; 2011 Mar; 11(6):552-8. PubMed ID: 21282974
[TBL] [Abstract] [Full Text] [Related]
